Nicholas Bruns, OD
Optometrist · Flint, MINPI 1902288558
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $174,620 of the $237,597 with a category attached, or 73.5%. Rxsight Inc accounts for 73.1% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $97,301, more than ten times the $1,561 reported in 2019. Among optometrist clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $733.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$174K
- Bausch & Lomb Americas Inc.$40K
- Glaukos Corporation$9K
- Lumibird Medical Inc.$5K
- Alcon$2K
- AbbVie$2K
- plus $5K from 17 others
Across 4 payments — averaging $4404.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$18K
What the payments were for
- Consulting fees$174,62073%
- Speaking & faculty fees$37,22216%
- Travel & lodging$6,6993%
- Food & beverage$11,8365%
- Education$980%
- Gifts$7,1233%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 84 | $173,725 |
| Bausch & Lomb Americas Inc. | 100 | $39,685 |
| Glaukos Corporation | 18 | $8,865 |
| Lumibird Medical Inc. | 2 | $5,419 |
| Alcon | 25 | $2,492 |
| AbbVie(2 entities) | 18 | $2,282 |
| Lensar, Inc. | 2 | $2,100 |
| Harrow Eye, LLC | 8 | $509 |
| Carl Zeiss Meditec USA, Inc. | 7 | $433 |
| Sun Pharmaceutical Industries Inc. | 8 | $414 |
| Tarsus Pharmaceuticals, Inc. | 10 | $371 |
| Biotissue Holdings Inc. | 5 | $229 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $218 |
| Dompe US, Inc. | 6 | $188 |
| The Cameron-ehlen Group, Inc. | 5 | $178 |
| Amgen(2 entities) | 2 | $139 |
| Oyster Point Pharma, Inc. | 4 | $85 |
| Thea Pharma Inc. | 3 | $67 |
| Johnson & Johnson Vision Care, Inc. | 4 | $60 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $55 |
| Aerie Pharmaceuticals, Inc. | 2 | $38 |
| Carl Zeiss Meditec, Inc. | 1 | $32 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$133,815
- RXSIGHT INJECTOR HANDPIECE$133,815
- RXSIGHT INJECTOR CARTRIDGE$133,815
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$133,815
- LIGHT ADJUSTABLE LENS (LAL)$108,300
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$39,246
- XIIDRA$35,530
- MIEBO$35,364
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$25,515
- Travoprost Intraocular Implant - iDose$3,043
- LENSAR LASER SYSTEM$2,100
- DAILIES$953
- enVista Aspire IOL$913
- TENEO$913
- STELLARIS ELITE$913
- TRYPTYR$900
- AIR OPTIX$569
- VYZULTA$494
- CE-marked KXLA system$450
- iDoseTR$425
How this compares
$237,597 in reported general payments places this provider in the 95th percentile of 1,523 optometrist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 29 | $34,575 |
| MieboPerfluorohexyloctane/Pf | 33 | $27,927 |
| XiidraLifitegrast | 22 | $27,226 |
| VyzultaLatanoprostene Bunod | 24 | $15,395 |
| Cyclosporine | 11 | $9,850 |
| LumiganBimatoprost | 11 | $5,987 |
| Latanoprost | 272 | $3,599 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $3,486 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 99 | $1,517 |
| Prednisolone Acetate | 38 | $1,239 |
| Timolol Maleate | 84 | $1,014 |
| Ketorolac Tromethamine | 28 | $797 |
| Brimonidine Tartrate | 83 | $615 |
| Dorzolamide Hcl | 27 | $487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $39,685 | $70,54879 claims |
| AbbVieRestasis, Lumigan | $2,282 | $40,56240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,523 optometrist providers in Michigan.
Other optometrist in Flint
- Jamie KuzniarBloomfield$473K
- Monica JohnsonbaughGrosse Pointe$393K
- Jay CrankGrand Rapids$209K
- Jeffrey VaranelliWarren$204K
- Thomas RothAnn Arbor$98K
- Frances Poma NowinskiBloomfield Twp$91K
- Michael LipsonWalled Lake$77K
- Stephanie RamdassBig Rapids$59K
- Robert FarrellMount Clemens$55K
- Steven BennettAnn Arbor$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.